media – Page 15 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Lukang Pharmaceutical raises 1.2 billion yuan through private placement to build a high-end intelligent manufacturing workshop for formulations and a biopesticide base

On December 20th, Lu Kang Pharmaceutical announced that the company plans to issue stocks to no more than 35 eligible investors, including the controlling shareholder Hualu Group, with a total fundraising amount of no more than 1.2 billion yuan. After deducting the issuance expenses, the funds will be used for the construction of high-end intelligent manufacturing workshops (total investment 442 million yuan), biopesticide base construction (total investment 432 million yuan), new drug research and development projects (total investment 210 million yuan), and supplementary working capital (200 million yuan). According to the official website, Lu Kang Pharmaceutical is a state-owned comprehensive pharmaceutical enterprise established in 1966. It was listed on the main board of the Shanghai Stock Exchange in 1997 and became a subsidiary of Hualu Holdings Group Co., Ltd. (hereinafter referred to as “Hualu Group”) in 2006. For the 1.2 billion yuan private placement fundraising, Lu Kang Pharmaceutical stated that ...
- Source: drugdu
- 121
- January 1, 2025
Yiming Biotech Completes RMB 200 Million Pre-D Round of Financing

Recently, Jiangsu Yiming Biotechnology Co., Ltd. (hereinafter referred to as “Yiming Biotech”) announced the successful completion of a new round of strategic financing of nearly RMB 200 million. This Pre-D round of financing was jointly invested by Beijing Changping Industrial Development Investment Fund and Beijing Pharmaceutical and Health Industry Investment Fund. It is another round of financing obtained by Yiming Biotech after the C+ round of financing in April 2023. Yiming Biotech said that as a bridge for ATMPs to go global and commercialize, it has been recognized and strongly supported by multiple investors in the current complex market environment. This round of financing will be used to further support the construction of Yiming Biotech’s ATMPs CDMO commercial production base, promote technology iteration, enhance the service capabilities of the CDMO global service network, consolidate the company’s core competitiveness in the ATMPs drug technology track, and create a large CDMO service ...
- Source: drugdu
- 69
- January 1, 2025
744 million! Medical Device Dark Horse completes C round of financing again

Recently, Precision Neuroscience (hereinafter referred to as Precision) announced that it has completed a new round of C round of financing of US$102 million (approximately RMB 744 million), bringing its total funds to US$155 million. Investors participating in this round of financing include General Equity Holdings, B Capital, Stanley F. Druckenmiller’s Duquesne Family Office and Steadview Capital. This round of financing will be used to expand Precision’s team, advance clinical research, and improve future versions of its artificial intelligence-driven brain implants. These implants are designed to enable severely paralyzed users to operate digital devices such as computers and smartphones simply by thinking. On November 6 this year, Precision also completed a C round of financing, with a financing scale of US$93 million (approximately RMB 679 million). Founded in 2021, Precision is a company focused on developing brain-computer interface (BCI) technology. Its goal is to bring advanced brain-computer interface technology to ...
- Source: drugdu
- 70
- January 1, 2025
【EXPERT Q&A】What qualifications do you need to export Class II medical devices to Japan?

Drugdu.com expert’s response: Exporting Class II Medical Devices to Japan requires compliance with Japan’s Pharmaceutical and Medical Device Act (PMD Act). Here are the primary qualifications and steps required: Determining Product Classification and JMDN Code: According to the PMD Act, medical devices are classified into I, II Special Control, II Controlled, III, and IV categories. It is necessary to determine the specific classification and JMDN code for the exported Class II medical devices. Manufacturer Registration: Foreign manufacturers must register their manufacturer information with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), including details on product design, production, and key processes. QMS Factory Audit: For Class II Special Control products, an application for a Quality Management System (QMS) factory audit must be submitted to the authorized certification body, PCB. For other Class II products, as well as Class III and IV products, an application for a QMS factory audit must be submitted ...
- Source: drugdu
- 110
- January 1, 2025
Welcome 2025! 🌟

Here’s to a new year filled with fresh opportunities and continued success. May 2025 be your most rewarding year yet!
- Source: drugdu
- 218
- January 1, 2025
The Rise of Domestic Production

Proton therapy is known as the “crown jewel” of tumor radiotherapy for its excellent performance, representing the highest level of radiotherapy technology. This technology utilizes the high-energy properties of proton beams to accurately strike tumor tissues while minimizing damage to surrounding normal tissues, bringing unprecedented treatment hope to cancer patients. According to the latest statistics, the number of proton heavy ion therapy centers worldwide has exceeded one hundred, which fully demonstrates the widespread recognition and application of proton therapy technology worldwide. According to market predictions, the global proton therapy market is expected to reach nearly 1.6 billion US dollars by 2031, which fully reflects the enormous potential and broad prospects of proton therapy technology. As 2024 is coming to an end, Instrumental Home has conducted a statistical analysis of the progress of proton therapy system projects in mainland China (based on public reports), and found that there are already 7 ...
- Source: drugdu
- 111
- January 1, 2025
Huiminbao’s “prisoner’s dilemma”

“Two people in my family were hospitalized, and both had Huiminbao, but not a penny was reimbursed.” When asked whether he would renew Huiminbao, netizen A answered like this. The subtext is: not renewing. It seems to be a very common thing to buy Huiminbao but not get protection. Behind this, it may also be Huiminbao’s helpless move. The nature of universal benefits has led to its extremely wide audience, but in order to avoid losses, Huiminbao has to set a relatively high deductible. In the past, the deductible of some products exceeded 20,000 yuan. However, most of the 20,000 yuan paid out of pocket in addition to medical insurance reimbursement is for major diseases. This also makes Huiminbao look more like major disease insurance, which has little to do with the market’s perception of “benefiting the people”. Of course, there are also Huiminbao with higher compensation rates, but they ...
- Source: drugdu
- 156
- January 1, 2025
Pioneer in going global, Sinopharm brings good news again. Inflixi, a newly introduced product, has been approved in Indonesia

Recently, Sinopharm (stock code: 688136) introduced its product – Infliximab for Injection (class stop) ®） Successfully approved for listing in Indonesia. The Southeast Asian pharmaceutical market has always been one of Sinopharm’s important advantage markets overseas. The approval of Inflixi in Indonesia further expands the sales area of the drug and provides new treatment options for local patients. Quickly approved for listing, Inflixi’s overseas progress refreshes Infliximab for injection (class stop) ®）， Approved for marketing by the National Medical Products Administration in July 2021, it is the first domestically approved biosimilar drug of Infliximab, mainly used for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, adult ulcerative colitis, adult and children over 6 years old with Crohn’s disease and fistula Crohn’s disease. In 2021 and 2022, Sinovac Pharmaceutical and Taizhou Mabotaike Pharmaceutical Co., Ltd. signed agreements to obtain biosimilars of Infliximab (class stop) ®） Commercial rights in over 30 countries ...
- Source: drugdu
- 86
- December 31, 2024
The R&D investment of 26.32 million yuan for external authorization will receive over 500 million yuan in down payment! How was “BD expert” Hengrui Medicine refined?

On the evening of December 29th, Hengrui Pharmaceutical (600276. SH) announced that it has reached an agreement with American biotechnology company IDEAYA Biosciences to license the exclusive rights to develop, produce, and commercialize the Class 1 injectable drug SHR-4849, which has independent intellectual property rights, to IDEAYA Biosciences worldwide for a fee, except for Greater China. Public information shows that SHR-4849 is an antibody drug conjugate (ADC) targeting DLL3, and its payload is a topoisomerase inhibitor (TOPOi). DLL3 is expressed in various solid tumors, including small cell lung cancer and neuroendocrine tumors, but its expression is limited in normal tissues. SHR-4849 exhibits strong proliferative inhibitory activity against different tumor cell lines with high expression of DLL3. SHR-4849 has a significant bystander effect and can kill DLL3 overexpressing cells by releasing toxins. Currently, there are no DLL3 ADC products approved for market worldwide. According to the announcement from Hengrui Pharmaceutical in ...
- Source: drugdu
- 110
- December 31, 2024
The world’s first batch! Daiichi Sankyo’s TROP-2 ADCs have been approved for market launch

On December 27, Daiichi Sankyo announced that its TROP-2 ADC product Datopotamab deruxtecan (Dato DXd, Dedabothumab, trade name: Datoway) was approved for marketing in Japan for the treatment of adult breast cancer patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+or IHC 2+/ISH -), who had received chemotherapy and could not be resected or relapsed. Dato DXd is the first TROP-2 ADC drug approved to treat HR positive and HER2 negative breast cancer in Japan, and also the second ADC drug approved to be developed based on Daiichi Sankyo DXd ADC technology. The drug was jointly developed by AstraZeneca, the First and Third Republics, and has been applied for marketing in the United States (NSCLC, HR+/HER2- breast cancer), the European Union (NSCLC, HR+/HER2- breast cancer), and China (HR+/HER2- breast cancer). This approval is based on data from a key Phase III clinical TROPION-Breast01 study. The TROPION-Breast01 study ...
- Source: drugdu
- 126
- December 31, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.